Results 221 to 230 of about 182,433 (270)

Differential Antiviral Effects of Pegylated Interferon-α2a and Pegylated Interferon-α2b in Chronic Hepatitis C

Clinical Drug Investigation, 2014
Pegylated interferon (peg-IFN)-α2a and -α2b show different pharmacokinetic properties but are used interchangeably for hepatitis C treatment in traditional dual combinations and with newer agents. We assessed whether peg-IFN antiviral effects vary with peg-IFN subtype, affecting viral response in a differential manner.Chronic hepatitis C patients ...
DURANTE MANGONI, Emanuele, Parrella A, Iossa D, Andini R, Molaro R, Battimelli C, Sodano G, UTILI, Riccardo   +7 more
openaire   +3 more sources

Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta

International Immunopharmacology, 2018
Because PEGylated molecules exhibit different physicochemical properties from those of the parent molecules, PEGylated interferonβ-1a (pegIFNβ-1a) may be able to be used with retained bioactivity in Multiple Sclerosis (MS) patients who have previously developed neutralizing antibodies (NABs) to recombinant interferonβ (rIFNβ).
Francesca, Gilli, Adrianna L, De La Torre, Darlene B, Royce, Andrew R, Pachner   +3 more
openaire   +2 more sources

Early virologic response with pegylated interferons

Digestive and Liver Disease, 2004
Recently, 12-week evaluation of viral response has been recommended as a means of reducing antiviral treatment morbidity and costs. The development of early stopping rules relies on an important assumption: rules must minimise discontinuation of treatment in patients who might ultimately respond after completion of the full course of therapy ...
openaire   +2 more sources

Pegylated interferons.

Reviews in gastroenterological disorders, 2002
Interferon therapy for chronic hepatitis C is not a cure, but it is able to decrease the viral load and may decrease the risk of complications (e.g., cirrhosis, liver failure, liver cancer). Pegylation of the interferon increases the amount of time the interferon remains in the body by increasing the size of the interferon molecule. Increasing molecule
openaire   +1 more source

Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C

Drugs, 2013
Results of trials and meta-analyses comparing pegylated interferon (PEG-IFN)-α2a and PEG-IFN-α2b for the treatment of chronic hepatitis C are conflicting.Our objective was to determine which PEG-IFN (α2a or α2b), in association with ribavirin, is the most effective for the treatment of chronic hepatitis C by performing an updated meta-analysis.MEDLINE (
Nicolas, Flori, Natalie, Funakoshi, Yohan, Duny, Jean-Christophe, Valats, Michael, Bismuth, Dimitri, Christophorou, Jean-Pierre, Daurès, Pierre, Blanc   +7 more
openaire   +2 more sources

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders†‡

Hepatology, 2009
Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).
Vinod K, Rustgi, William M, Lee, Eric, Lawitz, Stuart C, Gordon, Nezam, Afdhal, Fred, Poordad, Herbert L, Bonkovsky, Leif, Bengtsson, Gurudatt, Chandorkar, Matthew, Harding, Lindsay, McNair, Molly, Aalyson, John, Alam, Robert, Kauffman, Shahin, Gharakhanian, John G, McHutchison   +15 more
openaire   +2 more sources

Pegylated Interferons for the Treatment of Chronic Hepatitis B

Recent Patents on Anti-Infective Drug Discovery, 2006
Five drugs are approved for the treatment of chronic hepatitis B: conventional interferon (IFN) alfa, lamivudine, adefovir dipivoxil, pegylated interferon (peginterferon) alfa-2a and entecavir. Conventional IFN monotherapy has a narrow range of efficacy, should be administered subcutaneously and is commonly associated with adverse effects.
Chun-Jen, Liu, Jia-Horng, Kao
openaire   +2 more sources

Hepatitis C and treatment with pegylated interferon and ribavirin

The International Journal of Biochemistry & Cell Biology, 2004
Hepatitis C is a hepatotropic RNA virus with a propensity to cause chronic infection, causing a worldwide burden of chronic hepatitis, cirrhosis and hepatocellular carcinoma. Both viral elimination and hepatocellular damage are thought to be immune mediated with T-helper and cytotoxic T-lymphocytes central to these events.
James, Gotto, Geoffrey M, Dusheiko
openaire   +2 more sources

Emerging strategies for pegylated interferon combination therapy

Nature Clinical Practice Gastroenterology & Hepatology, 2007
Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication.
openaire   +2 more sources

Pegylated interferons

Journal of Drug Evaluation, 2004
Raymond D'Souza, Graham Foster
openaire   +1 more source